Top Health News: Breakthroughs, Investments, and Market Trends

Recent health news highlights Regeneron's financial success driven by eczema and eye treatments, Eli Lilly's weight loss drug reducing heart failure risks, UK family doctors striking, Sanofi's major insulin investment, Biogen's profit forecast despite MS drug sales decline, R1 RCM's private acquisition, Haleon's profit growth, Japan backing Eli Lilly's dementia drug, Moderna reducing its vaccine sales forecast, and Novo Nordisk launching its weight loss drug in Australia.

Regeneron Pharmaceuticals reported exceeding revenue and profit estimates for the second quarter, driven by its eczema and eye drugs. Eli Lilly announced that trial results showed its weight loss drug tirzepatide reduced heart failure risks by 38%. In England, family doctors in the NHS voted overwhelmingly to take industrial action for the first time in 60 years over funding and contract changes. French drugmaker Sanofi said it will invest 1.3 billion euros in a new insulin production facility in Frankfurt. Biogen revised its full-year earnings forecast upwards, driven by new treatments and cost-cutting programs as it faces declining sales of multiple sclerosis medications. Healthcare tech firm R1 RCM will be taken private in an $8.9 billion deal by TowerBrook Capital Partners and Clayton, Dubilier & Rice. Haleon predicted high single-digit growth in organic operating profit for 2024, amidst strong demand for its products. A Japanese health ministry panel recommended approving Eli Lilly's dementia treatment donanemab. Moderna reduced its 2024 sales forecast for COVID-19 and RSV vaccines due to expected low sales in the EU. Finally, Novo Nordisk launched its popular weight-loss drug Wegovy in Australia.

(With inputs from agencies.)